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Abstract
Peptide substrates sensitive for a certain protein kinase could be important for new-drug development and to understand
the mechanism of diseases. Rho-associated kinase (Rho-kinase/ROCK) is a serine/threonine kinase, and plays an important
part in cardiovascular disease, migration and invasion of tumor cells, and in neurological disorders. The purpose of this
study was to find substrates with high affinity and sensitivity for ROCK2. We synthesized 136 peptide substrates from
protein substrates for ROCK2 with different lengths and charged peptides. Incorporation of
32P [counts per minute (CPM)]
for each peptide substrate was determined by the radiolabel assay using [c-
32P]ATP. When the top five peptide substrates
showing high CPMs (R4, R22, R133, R134, and R135) were phosphorylated by other enzymes (PKA, PKCa, and ERK1), R22,
R133, and R135 displayed the highest CPM level for ROCK2 compared with other enzymes, whereas R4 and R134 showed
similar CPM levels for ROCK2 and PKCa. We hypothesize that R22, R133, and R135 can be useful peptide substrates for
ROCK2.
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Introduction
Phosphorylation by protein kinases plays an essential part in the
signal transduction pathways that regulate cellular functions in
response toextracellularsignals.Itisalsoageneralmechanismforthe
control of intracellular processes [1]. Designing specific peptide
substrates for a certain protein kinase is indispensable for the
characterization of (or search for) substrate proteins for enzymes, and
is also important in explorations for new drugs. In general, peptide
substrates specific to a certain protein kinase are identified using
genetic variants of protein substrates and synthetic peptides [2–4].
Rho-associated kinase (Rho-kinase/ROCK; hereafter referred
to as ROCK) is a serine/threonine kinase and plays an important
part in various cellular functions. These include the contraction of
smooth muscle, cell adhesion, and cytokinesis [5,6]. Over-
expression of this enzyme has been associated with cardiovascular
diseases such as hypertension and cerebral and coronary
vasospasm [7–9]. Moreover, ROCK is closely associated with
the migration and invasion of tumor cells [10,11]. Recent studies
suggest that inhibition of ROCK not only increases cerebral blood
flow and leads to protection against stroke, but enhances
functional recovery in injured spinal cords [12–14]. Thus, ROCK
could be a potential therapeutic target for tumors, neurological
disorders and cardiovascular diseases.
ROCK is divided into two isozymes: ROCK1 (ROCKb)a n d
ROCK2 (ROCKa) [5,6]. The latter is mainly expressed in the
brain, heart, and skeletal muscle, and ROCK1 has been identified
in the spleen, lung, liver, testis, and kidney [15]. Many protein
substrates for ROCK and their substrate sequences have been
reported. ROCK can phosphorylate calponin [16]; LIM-kinase 1
(LIMK1) [17]; adducin [18]; intermediate filaments (vimentin [19],
neurofilament-L [20], and glial fibrillary acidic protein (GFAP)
[21]); collapsin response mediator protein 2 (CRMP2) [22]; tau
[23]; microtubule-associated protein 2 (MAP2) [23]; ERM family
(ezrin/radixin/moesin) [24]; myosin binding subunit (MBS) [25];
myosin light-chain (MLC) [26]; myristoylated alanine-rich C kinase
substrate (MARCKS) [27,28]; Rho E [29]; zipper-interacting
protein kinase (ZIPK) [30]; LIMK2 [31] and endophilin A1 [32].
The purpose of the present study was to find substrates with high
affinity and sensitivity for ROCK2. We synthesized 136 peptide
substrates from proteinsubstrates forROCK2withdifferent lengths
and charged peptides. After determining the incorporation of
radioactivity (counts per minute (CPM)) for each peptide substrate
by the radiolabel assay using [c-
32P]ATP, kinetic properties for the
final five top-ranked substrates were analyzed. We also examined
the affinities of five substrates for other kinases (extracellular signal-
regulated kinase 1 (ERK1), protein kinase A (PKA), and protein
kinase C (PKC)a) showing similar consensus sequences and
interactive functions in intracellular signal transduction to ROCKs.
Results
To search for peptide substrates with high affinity and sensitivity
for ROCK2, we synthesized 136 peptide substrates on the basis of
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and Table S2). These peptide substrates showed a different
number of charged peptide residues or amino-acid residues.
Peptide substrates had a basic amino acid (Arg or Lys) at amino-
terminal position 22o r23 of the phosphorylated sites (Ser and
Thr). Moreover, most amino acids at the +2 carboxyl-terminal
position were basic or hydrophobic (Arg, Lys, Phe, Leu, Trp, or
Val) (Table S2).
We determined the radioactivity (in counts per minute (CPM))
for each peptide substrate by the radiolabel assay using
[c-
32P]ATP (Fig. 1). Peptide substrates were divided into four
groups from the results of radioactivity. Conversely, five peptide
substrates showing CPM values of .35,000 for ROCK2 were in
the order R134 (KSARKKRYTVVGNPYWM).R4 (RAKYK-
TLRQIR).R22 (KPARKKRYTVVGNPYWM).R133 (KSDR-
KKRYTVVGNPYWM).R135 (KADRKKRYTVVGNPYWM)
(Fig. 2).
The Ser:Thr ratio for the total number of phosphorylation sites
used in this study was 9:12. The substitution of Ser for Thr at the
phosphorylation site led to a tendency to a decrease in the
radioactivity (see R1–6 and R7–12, R64–67 and R68–71, R72–75
and R76–79, R80–82 and R83–85, and R86–88 and R89–91)
(Fig. 1). Although the observation was not universal, the change of
negatively charged amino acids (Asp or Glu) into Ala or positively
charged amino acids tended to result in an increase in CPM.
However, the length of peptides had no or very little effect on
CPMs (Fig. 1 and Table S2).
Furthermore, the kinetic properties of five peptide substrates
showing high CPM for ROCK2 were analyzed. Values of Km and
Vmax for five peptide substrates ranged from 1.7 mM to 3.3 mM,
and from 8.6 pmol/min/mg to 14.9 pmol/min/mg, respectively
(Table 1).
The consensus sequence of the ROCK2 phosphorylation site
was considered to be R/KXXS/T or R/KXS/T (R, arginine; K,
lysine; X, any amino acid; S, serine; and T, threonine) [5,33]
(Table S2). These consensus sequences were similar to other
protein kinases (e.g., PKA and PKC). PKA recognizes the
phosphorylation motifs R/KXS/T and R/KXXS/T [34,35].
Consensus phosphorylation site motifs for PKC were identified to
be R/KXXS/T, R/KXS/T, R/KXXS/TXR/K, or R/KXS/
TXR/K [35,36]. Mitogen-activated protein kinase (MAPK) can
recognize the phosphorylation motif XS/TPX (P, proline) [37].
Five peptide substrates that showed CPM of .35,000 for ROCK2
were phosphorylated with PKA, PKCa (isozyme of PKC), and
ERK1 (isozyme of MAPK). R4 and R134 showed high CPM for
ROCK2 and PKCa. R22, R133, and R135 showed much higher
CPM for ROCK2 than that of PKCa (Fig. 3).
Several studies have reported that replacement of phosphor-
ylatable amino acids with alanine can lead to an inhibitor peptide
for each enzyme [38,39]. Thus, we examined if peptides that
Figure 1. Counts per minute (CPM) levels for 136 peptide substrates. Each peptide substrate was analyzed by the radiolabel assay using
[c-
32P]ATP.
doi:10.1371/journal.pone.0022699.g001
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phosphorylation of substrate peptide by ROCK2. The phosphor-
ylatable threonine of five peptide substrates (R4, R22, R133,
R134, and R135) was replaced with alanine and used as inhibitor
peptides. The lowest Ki (11.6 mM) in a competitive manner was
obtained for R22 with alanine instead of threonine (Table 2).
Discussion
There have been many efforts to search for peptide substrates
with high affinity and sensitivity to ROCK2. However, different
experimental methods make selecting substrates for ROCK2 quite
difficult. Moreover, the affinity and sensitivity of substrates for
ROCK2 can be influenced by several factors. These include the
peptide length and the number of charged peptides [38,40–42],
but these factors were not investigated in previous studies.
We synthesized 136 peptide substrates for ROCK2 with
different lengths and charged peptides, and analyzed their ability
for phosphorylation. When negatively charged amino acids (Asp
and Glu) were replaced by Ala or a positively charged amino acid
(Arg), resulting in an increase in the positive charge density in
peptide substrate, a tendency to an increase in the radioactivity
was identified. For example, a higher CPM value was identified for
R4 than for R1, R38 than R33, and R134 than R133. The length
of peptide substrate had no or little effect on the level of
radioactivity. In general, shortening of peptide substrates de-
creased the affinity for the enzyme (i.e., increased the Km value).
However, the peptide length showed minor changes in the Vmax
value [38,40,41]. These data showed that radioactivity was not
affected by the length of peptide substrates, but that the change of
negatively charged amino acids into Ala or positively charged
amino acids could increase the radioactivity values.
PKA and PKCa broadly recognize ROCK phosphorylation
sites because of their similar consensus sequences to the ROCK
phosphorylation motif. Our previous study showed that ROCK
substrates can be good substrates for PKA and/or PKCa. Among
18 ROCK phosphorylation sites, 14 sites (Thr-184 of calponin;
Thr-508 of LIMK1; Ser-71 of vimentin; Ser-57 of neurofilament-
L; Thr-7, Ser-13, and Ser-34 of GFAP; Thr-555 of CRMP2; Ser-
409 of tau; Ser-1796 of MAP2; Ser-854 of MBS; Thr567/564/558
of the ERM family; Ser-19 of MLC; and Ser-159 of MARCKS)
were phosphorylated by PKA and/or PKCa [33]. Moreover,
there was a close function in intracellular signal transduction
between ROCK and PKCa, ERK1, or PKA. The interactive role
of ROCK and PKCa has been reported in the actin–myosin
interaction [43] and in the contraction of vascular smooth muscle
[44,45]. MLC phosphorylation was stimulated by ROCK and
Figure 2. Classification of peptide substrates. Four groups were divided from the results of radioactivity (i.e., CPM).
doi:10.1371/journal.pone.0022699.g002
Table 1. Kinetic properties for five peptide substrates
showing CPM.35,000.
Number of peptide
substrate Km (mM) Vmax (pmol/min/mg) Vmax/Km
R4 1.7 14.2 8.4
R22 1.9 10.3 5.4
R133 3.6 10.0 2.8
R134 3.3 14.9 4.5
R135 3.2 8.6 2.7
doi:10.1371/journal.pone.0022699.t001
Figure 3. Phosphorylation of the top five peptide substrates
(R4, R22, R133, R134, and R135) for ROCK2 by other enzymes
(PKA, PKCa, or ERK1). Each peptide substrate was analyzed by the
radiolabel assay using [c-
32P]ATP. CPM, counts per minute.
doi:10.1371/journal.pone.0022699.g003
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inhibitors [44,45]. RhoA phosphorylation at Ser 188 by PKA
blocks the ROCK pathways, resulting in activation of MLC
phosphatase and the relaxation of smooth muscle [46]. Activated
PKA can also facilitate axon formation by inhibiting RhoA, but
ROCK has opposite effects on axon formation [47]. ROCK has
an effect on translocation of ERK1 to the cellular nucleus, leading
to proliferation of smooth muscle cells in the pulmonary artery
[48]. ERK1 activation by ROCK stimulates: 1) force-induced
osteopontin expression in human periodontal ligament fibroblasts
through focal adhesion kinase signaling [49]; and 2) migration and
proliferation of glioblastoma cells [50]. The observations noted
above mean that PKA, PKCa, and ERK1 directly and/or
indirectly participate in the signal transduction pathways of
ROCK. Thus, we examined if five peptide substrates (R4, R22,
R133, R134, and R135) showing high CPM values (.35,000) for
ROCK2 could be phosphorylated by other enzymes (PKA,
PKCa, or ERK1). R22, R133, and R135 displayed higher CPM
levels for ROCK2 than the other enzymes, whereas R4 and R134
showed similar CPM levels for ROCK2 and PKCa (Fig. 3). These
results suggested that R22 and R133 could be useful peptide
substrates for ROCK2, and that R4 and R134 could be useful
peptide substrates for ROCK2 and PKCa.
Replacement of phosphorylation sites with alanine is used to
develop inhibitor peptides. In general, peptides showing higher
affinity (i.e., low Km) than lower affinity (i.e., high Km) become much
more effective inhibitor peptides when phosphorylation sites are
substituted by alanine. In the present study, we examined if five
peptides in which a phosphorylatable amino acid (threonine) was
replaced with alanine could be used as potent competitive
inhibitors of ROCK2. The R22 peptide with alanine instead of
threonine showed the lowest Ki (11.6 mM) (Table 2).
In conclusion, there has been an increasing interest in ROCKs
as therapeutic targets of cardiovascular disease, migration and
invasion of tumor cells, and neurological disorders. Peptide
substrates with high affinity and sensitivity to ROCK2 are
important in new-drug developments and in understanding the
cellular signals involved. In the present study, 136 peptide
substrates from protein substrates for ROCK2 were synthesized
and the radioactivity of each peptide substrate analyzed. From
CPM results and phosphorylation reactions with other enzymes
(PKA, PKCa, and ERK1), we found three peptides (R22, R133,
and R135) to be useful peptide substrates for ROCK2.
Materials and Methods
Syntheses of peptide substrates
Peptide substrates were synthesized using an automatic peptide
synthesizer according to standard Fmoc-chemistry procedures.
After treatment with trifluoroacetic acid (TFA), peptides were
purified on an Inertsil ODS-3 column (250620 mm, 3.5 mm; GL
Sciences, Tokyo, Japan) using a BioCAD Perfusion Chromatog-
raphy System (Ikemoto Scientific Technology, Tokyo, Japan) and
a linear A–B gradient at a flow rate of 8 mL/min where eluent A
was 0.1% TFA in water and eluent B was 0.1% TFA in
acetonitrile. The purity of synthetic peptide was identified by high-
performance liquid chromatography and matrix-assisted laser
desorption/ionization-time-of-flight mass spectrometry, and the
peptide with .95% purity was used for the phosphorylation
reaction.
Phosphorylation of peptide substrates by enzymes
The synthetic peptide S6K (KRRRLASLR) was used as a
control for ROCK2. Alphatomega (FKKQGSFKKK) [4] was
used for PKCa assays and ZIPK-T265 (KRRMTIAQSLEHS-
WIK) [30] for PKA assays. ERK assays employed 0.33 mg/mL
human myelin basic protein (MBP; Chemicon International,
Temecula, CA, USA).
The kinase activity of recombinant ROCK2 (Carna Biosci-
ences, Kobe, Japan), ERK1 (Upstate, Millipore, Temecula, CA,
USA), PKA (Promega, Madison, WI, USA), and PKCa (Sigma–
Aldrich, St. Louis, MO, USA) for the peptide substrates was
determined by measuring
32Pt r a n s f e rf r o m[ c-
32P]ATP into
substrate peptides according to manufacturer recommendations.
Phosphorylation reactions by ROCK2 were carried out in 25 mL
of buffer (5 mM 3-(N-morpholino)propanesulfonic acid (MOPS)
at pH 7.2, 2.5 mM beta-glycerophosphate, 1 mM ethylene glycol
tetra-acetic acid (EGTA), 4 mM MgCl2, 0.05 mM dithiothreitol
(DTT), and 100 mM adenosine triphosphate (ATP)) containing
peptides and 1.25 mg/ml ROCK2. For PKCa, phosphorylation
reactions were carried out in 25 mL of buffer (20 mM HEPES at
pH 7.4, 10 mM MgCl2, 1 mM CaCl2,1 0 0mMA T P ,4 0mg/mL
phosphatidylserine, and 20 mg/mL diacylglycerol) containing
peptides and 0.5 mg/mL PKCa. Phosphorylation reactions by
PKA were carried out in 25 mL of buffer (50 mM HEPES at
pH 7.4, 1 mM CaCl2, 10 mM MgCl2,1 0 0mM ATP) containing
peptides and 1.6 mg/mL PKA. For ERK1, phosphorylation
reactions were carried out in 25 mL of buffer (25 mM Tris-HCl at
pH 7.5, 20 mM EGTA, 15 mM magnesium acetate, and 100 mM
ATP) containing peptides and 0.5 mg/mL ERK1. For each
experimental condition, values for control reactions lacking
substrate peptides were subtracted as blanks. The assay mixture
was incubated for 10 min at 25uC, and the reaction terminated
by the addition of 5 mL of 30% trichloroacetic acid (TCA). The
reaction mixture (24 mL) was spotted onto P-81 phosphocellulose
membranes. The membranes were washed thrice with 5% TCA,
dried with acetone, and the radioactivity of each membrane
determined by liquid scintillation counting. Kinetic analyses of
enzyme activity were determined using the Lineweaver–Burk
plot.
Inhibition of phosphorylation by inhibitor peptides
The phosphorylatable amino acid (threonine) of five peptide
substrates (R4, R22, R133, R134, and R135) was replaced with
alanine. Inhibitory activity of these inhibitor peptides against
ROCK2 was examined using S6K peptide (KRRRLASLR) as
a substrate; value of Km and Vmax for S6K was 3.1 mM and
23.1 pmol/min/mg, respectively. Ki values were obtained from
the Dixon plot and Lineweaver–Burk plot. Inhibitor peptides were
added into 25 mL of buffer (5 mM MOPS at pH 7.2, 2.5 mM
beta-glycerophosphate, 1 mM EGTA, 4 mM MgCl2, 0.05 mM
DTT, and 100 mM ATP) containing S6K substrate peptide and
1.25 mg/mL ROCK2.
Table 2. Ki values for five peptides with alanine instead of a
phosphorylatable threonine.
Number of peptide Ki (mM)
R4 86.6
R22 11.6
R133 .100
R134 29.2
R135 .100
doi:10.1371/journal.pone.0022699.t002
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